RIPK4 and urinary bladder carcinoma: HNTs were used to deliver therapeutic siRNA to target RIPK4 (receptor interacting protein kinase 4) which are highly expressed in bladder cancer cells.880 Studies have found that NPs coated with HNTs are more stable in the body, easily taken up by cells and accumulated in the bladder cancer lesion, thereby effectively inhibiting the occurrence and development of bladder cancer.